Comparisons of cancer patients’ survival and care in Europe up to 2007 showed that although more patients are surviving for at least five years after diagnosis, there are large variations in survival between countries, which are particularly significant in blood cancers. New analysis of data from the EUROCARE-5 trial in patients diagnosed after 2000 in European countries revealed that survival is generally low in Eastern Europe and high in Northern and Central Europe, which confirms trends highlighted in previous EUROCARE studies.
Presented at the European Cancer Conference (ECC) 2015 by Milena Sant, MD, of Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
